Cost-effectiveness analysis of pneumococcal conjugate vaccines, PCV21 vs PCV20, in adults aged ≥60 years in Germany.
BACKGROUND Higher-valency pneumococcal conjugate vaccines (PCVs) may reduce the burden of adult pneumococcal disease (PD), yet it is unclear whether higher acquisition costs are offset by improved health outcomes and cost savings. RESEARCH DESIGN AND METHODS A published state-transition Markov model simulated vaccine...